ClinicalTrials.gg

Program

orforglipron

Also written as “Orforglipron”, “LY3502970” and “[14C]-LY3502970”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension · Obesity, Abdominal · Renal Insufficiency, Chronic, led by Eli Lilly.

Furthest: phase 3, since Mar 27, 202350 company-led studies, 17 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly5017 open or runningphase 3since Mar 27, 2023Apr 25, 2019Feb 2027phase 3 · NCT06672549

Also a collaborator on its studies: quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 28 studies since Apr 25, 2019.

  1. May 29, 2024Phase 1 study in ObesityNCT06440980 · 533 enrolled · United States
  2. Sep 3, 2024Phase 3 study in ObesityNCT06584916 · 376 enrolled · United States, Puerto Rico
  3. Oct 17, 2024Phase 3 study in OverweightNCT06649045 · 712 enrolled · United States, Argentina, Brazil and more
  4. Nov 1, 20242 phase 3 studies in ObesityNCT06672939, NCT06672549
  5. Nov 14, 20242 phase 1 studies in HealthyNCT06692348, NCT06704763
  6. Jan 27, 2025Phase 1 study in ObesityNCT06824051 · 120 enrolled · United States
  7. Apr 21, 20253 phase 3 studies in HypertensionNCT06952530, NCT06948435, NCT06948422
  8. May 7, 20253 phase 3 studies in ObesityNCT06993792, NCT06972472, NCT06972459
  9. Sep 2, 20252 phase 3 studiesNCT07153471, NCT07202884
  10. Oct 30, 2025Phase 3 study in Peripheral Arterial DiseaseNCT07223593 · 1,205 planned · United States, Argentina, Australia and more
  11. Nov 17, 2025Phase 3 study in Renal Insufficiency, ChronicNCT07241390 · 7,140 planned · Argentina, Australia, Austria and more
  12. May 22, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07613307 · 130 planned · India, Saudi Arabia, South Africa and more
  13. Jun 22, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07668336 · 170 planned · United States, Belgium, Brazil and more
  14. Aug 25, 20262 phase 3 studiesNCT07790861, NCT07794579

Ahead

  1. Feb 2027Primary completion: phase 3 study in ObesityNCT06672549
  2. May 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07613307
  3. Aug 2027Primary completion: phase 3 study in ObesityNCT06993792
  4. Aug 2027Primary completion: phase 3 study in ObesityNCT06972472

TargetBeta

GLP1R →read by rule
“Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

All 50 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07794579Overweight · United States, Argentina, China and more3RecruitingAug 20292,001
NCT07790861Obesity · China3Not yet recruitingMar 2028192
NCT07668336Diabetes Mellitus, Type 2 · United States, Belgium, Brazil and more3RecruitingMar 2030170
NCT07613307Diabetes Mellitus, Type 2 · India, Saudi Arabia, South Africa and more3RecruitingMay 2027130
NCT07241390Renal Insufficiency, Chronic · Argentina, Australia, Austria and more3RecruitingAug 20317,140
NCT07223593Peripheral Arterial Disease · United States, Argentina, Australia and more3RecruitingJun 20281,205
NCT07202884Urinary Incontinence, Stress · United States, Canada, China and more3RecruitingMar 20281,000
NCT07153471Osteoarthritis · United States, Canada, China and more3Active, not recruitingApr 2028800
NCT06993792Obesity · United States, Argentina, China and more3Active, not recruitingAug 20271,400
NCT06972472Obesity · United States, Argentina, China and more3Active, not recruitingAug 2027600
NCT06972459Obesity · United States, Argentina, China and more3Active, not recruitingAug 2027800
NCT06952530Hypertension · United States, Argentina, China and more3Active, not recruitingSep 2027487
NCT06948435Hypertension · United States, Argentina, China and more3Active, not recruitingSep 2027487
NCT06948422Hypertension · United States, Argentina, China and more3Active, not recruitingSep 2027974
NCT06824051Obesity · United States1CompletedJan 26, 2026120
NCT06704763Healthy · United States1CompletedFeb 5, 202527
NCT06692348Healthy · Japan1CompletedJun 9, 202586
NCT06672939Obesity · United States, Israel, Italy and more3RecruitingDec 2027150
NCT06672549Obesity · United States, Belgium, Brazil and more3RecruitingFeb 2027125
NCT06649045Overweight · United States, Argentina, Brazil and more3CompletedJul 21, 2026712
NCT06584916Obesity · United States, Puerto Rico3CompletedNov 21, 2025376
NCT06440980Obesity · United States1CompletedJun 2, 2025533
NCT06370728Healthy · United States1CompletedJul 23, 202430
NCT06192108Diabetes Mellitus, Type 2 · United States, China, Germany and more3CompletedSep 26, 2025962
NCT06186622Obesity · United States1CompletedJul 10, 202450
NCT06109311Diabetes Mellitus, Type 2 · United States, Brazil, China and more3CompletedSep 15, 2025546
NCT06085482Healthy · United States1CompletedJan 5, 202410
NCT06045221Diabetes Mellitus, Type 2 · United States, Argentina, China and more3CompletedAug 22, 20251,698
NCT06023095Overweight · China1CompletedJul 29, 202424
NCT06010004Diabetes Mellitus, Type 2 · Japan3CompletedJun 5, 2025401
NCT05971940Diabetes Mellitus, Type 2 · United States, China, India and more3CompletedApr 3, 2025559
NCT05936138Renal Insufficiency · United States1CompletedApr 11, 202424
NCT05931380Obesity · Japan3CompletedJun 19, 2025238
NCT05882032Hepatic Insufficiency · United States1CompletedNov 18, 202429
NCT05872620Obesity · United States, Argentina, Australia and more3CompletedAug 8, 20251,613
NCT05869903Obesity · United States, Brazil, China and more3Active, not recruitingJul 25, 20253,127
NCT05841238Obesity · United States1CompletedSep 14, 202352
NCT05803421Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedMar 16, 20262,749
NCT05573230Healthy · Singapore1CompletedJan 17, 202332
NCT05469126Healthy · Singapore1CompletedNov 3, 202226
NCT05341089Healthy · Singapore1CompletedSep 1, 202239
NCT05313802Obesity · United States1CompletedSep 9, 202272
NCT05110794Healthy · Singapore1CompletedFeb 10, 202234
NCT05086445Diabetes Mellitus, Type 2 · Japan1CompletedSep 5, 202262
NCT05051579Obesity · United States, Canada, Hungary and more2CompletedAug 25, 2022272
NCT05051566Healthy · United Kingdom1CompletedApr 4, 202226
NCT05048719Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more2CompletedSep 30, 2022383
NCT04680767Healthy · United Kingdom1CompletedJul 3, 20216
NCT04426474Diabetes Mellitus, Type 2 · United States, Germany1CompletedJul 12, 202168
NCT03929744Healthy · United States1CompletedNov 2, 2020133

How it is read

Names in the registry

  • “Orforglipron”, 33 entries
  • “LY3502970”, 16 entries
  • “[14C]-LY3502970”, 1 entry
  • “[¹⁴C]-LY3502970”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.